Compare VST & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VST | TAK |
|---|---|---|
| Founded | 1882 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.1B | 52.4B |
| IPO Year | 2016 | N/A |
| Metric | VST | TAK |
|---|---|---|
| Price | $159.01 | $16.56 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $234.09 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 2.7M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | 0.59% | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $17,738,000,000.00 | N/A |
| Revenue This Year | $30.97 | $0.16 |
| Revenue Next Year | $9.19 | $1.22 |
| P/E Ratio | $55.03 | ★ $41.25 |
| Revenue Growth | ★ 2.98 | N/A |
| 52 Week Low | $132.66 | $12.99 |
| 52 Week High | $219.82 | $18.90 |
| Indicator | VST | TAK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.91 |
| Support Level | N/A | $16.24 |
| Resistance Level | N/A | $16.92 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 0.00 | 67.92 |
Vistra Corp. is one of the largest power producers and retail energy providers in the US. It owns 44 gigawatts of generation capacity, including natural gas (27 GW), nuclear (6.5 GW), coal (8.7 GW), and solar and battery storage (1.3 GW). The Cogentrix acquisition will add 5.5 GW of gas generation. Vistra's retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.